Page 486 - Read Online

Page 38 of 40 Maner et al. J Cancer Metastasis Treat 2020;6:37 I http://dx.doi.org/10.20517/2394-4722.2020.60

152. Wells GL. Melanoma - Dermatologic Disorders. Merck Manuals Professional Edition 2019. Available from: https://www.msdmanuals.
com/professional/dermatologic-disorders/cancers-of-the-skin/melanoma. [Last accessed on 7 Sep 2020]
153. Soufir N. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma
Study Group. Hum Mol Genet 1998;7:209-16.
154. Freedman DM, Sigurdson A, Rao RS, Hauptmann M, Alexander B, et al. Risk of melanoma among radiologic technologists in the United
States. Int J Cancer 2003;103:556-62.
155. Miura K, Olsen CM, Rea S, Marsden J, Green AC. Do airline pilots and cabin crew have raised risks of melanoma and other skin
cancers? Systematic review and meta-analysis. Br J Dermatol 2019;181:55-64.
156. Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clinic Proceedings 2012;87:991-1003.
157. Budden T, Davey RJ, Vilain RE, Ashton KA, Braye SG, et al. Repair of UVB-induced DNA damage is reduced in melanoma due to low
XPC and global genome repair. Oncotarget 2016;7:60940-53.
158. Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell
1996;85:27-37.
159. Sharpless E, Chin L. The INK4a/ARF locus and melanoma.Oncogene 2003;22:3092-8.
160. Palmieri G, Ombra M, Colombino M, Casula M, Sini M, et al. Multiple molecular pathways in melanomagenesis: characterization of
therapeutic targets. Front Oncol 2015;5:183.
161. Liu J, Fukunaga-Kalabis M, Li L, Herlyn M. Developmental pathways activated in melanocytes and melanoma. Arch Biochem Biophys
2014;563:13-21.
162. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.
163. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med
2005;353:2135-47.
164. Lopez-Bergami P, Fitchman B, Ronai ZE. Understanding signaling cascades in melanoma. Photochem Photobiol 2008;84:289-306.
165. Kunz M, Vera J. Modelling of protein kinase signaling pathways in melanoma and other cancers. Cancers 2019;11:465.
166. Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, et al. Roads to melanoma: key pathways and emerging players in
melanoma progression and oncogenic signaling. Biochim Biophys Acta 2016;1863:770-84.
167. Orouji E, Orouji A, Gaiser T, Larribère L, Gebhardt C, et al. MAP kinase pathway gene copy alterations inNRAS/BRAFwild-type
advanced melanoma. Int J Cancer 2016;138:2257-62.
168. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
169. Chen X, Wu Q, Depeille P, Chen P, Thornton S, et al. RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma.
Cancer Cell 2017;31:685-96.e6.
170. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
171. Broussard L, Howland A, Ryu S, Song K, Norris D, et al. Melanoma cell death mechanisms. Chonnam Med J 2018;54:135.
172. Abbaspour Babaei M, Kamalidehghan B, Saleem M, Zaman Huri H, Ahmadipour F. Receptor tyrosine kinase (c-Kit) inhibitors: a
potential therapeutic target in cancer cells. Drug Des Devel Ther 2016;10:2443-59.
173. Meng D, Carvajal RD. KIT as an oncogenic driver in melanoma: an update on clinical development. Am J Clin Dermatol 2019;20:315-23.
174. Sakaizawa K, Ashida A, Uchiyama A, Ito T, Fujisawa Y, et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in
Japanese melanoma patients. J Dermatol Sci 2015;80:33-7.
175. Kong Y, Si L, Zhu Y, Xu X, Corless CL, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer
Res 2011;17:1684-91.
176. Avagliano A, Fiume G, Pelagalli A, Sanità G, Ruocco MR, et al. Metabolic plasticity of melanoma cells and their crosstalk with tumor
microenvironment. Front Oncol 2020;10:722.
177. Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci 2015;72:1249-60.
178. Wellbrock C, Arozarena I. The complexity of the ERK/MAP-kinase pathway and the treatment of melanoma skin cancer. Front cell dev
biol 2016;4:33.
179. Buscà R, Berra E, Gaggioli C, Khaled M, Bille K, et al. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated
transcription factor (MITF) in melanoma cells. J Cell Biol 2005;170:49-59.
180. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, et al. Bcl2 regulation by the melanocyte master regulator mitf modulates
lineage survival and melanoma cell viability. Cell 2002;109:707-18.
181. Šestáková B, Ondrušová L, Vachtenheim J. Cell cycle inhibitor p21/WAF1/CIP1 as a cofactor of MITF expression in melanoma cells.
Pigment Cell Melanoma Res 2010;23:238-51.
182. McKibbin T. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies. Am J Manag Care
2015;21:S224-33.
183. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAAS, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1
checkpoint blockade. Cell 2017;170:1120-33.e17.
184. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res
2013;19:1021-34.
185. Zhang N, Wang L, Zhu G, Sun DJ, He H, et al. The association between trauma and melanoma in the Chinese population: a retrospective
study. J Eur Acad Dermatol Venereol 2013;28.
186. Möhrle M, Häfner HM. Is subungual melanoma related to trauma? Dermatology 2002;204:259-61.
187. Elmore JG, Elder DE, Barnhill RL, Knezevich SR, Longton GM, et al. Concordance and reproducibility of melanoma staging according